These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25977084)

  • 61. Memory and menopause: an unsolved puzzle.
    Prakapenka AV; Bimonte-Nelson HA
    Aging (Albany NY); 2018 Oct; 10(10):2541-2543. PubMed ID: 30321139
    [No Abstract]   [Full Text] [Related]  

  • 62. Linopirdine (DUP 996): cholinergic treatment of older adults using successive and non-successive tests.
    Börjesson A; Karlsson T; Adolfsson R; Rönnlund M; Nilsson L
    Neuropsychobiology; 1999; 40(2):78-85. PubMed ID: 10474062
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests.
    Perry W; Light GA; Davis H; Braff DL
    Schizophr Res; 2000 Dec; 46(2-3):167-74. PubMed ID: 11120428
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of the putative cognitive-enhancing ampakine, CX717, on attention and object recognition memory.
    Zheng Y; Balabhadrapatruni S; Masumura C; Darlington CL; Smith PF
    Curr Alzheimer Res; 2011 Dec; 8(8):876-82. PubMed ID: 22171951
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Enhancing cognition through pharmacological and environmental interventions: Examples from preclinical models of neurodevelopmental disorders.
    Morè L; Lauterborn JC; Papaleo F; Brambilla R
    Neurosci Biobehav Rev; 2020 Mar; 110():28-45. PubMed ID: 30981451
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cognition enhancers in age-related cognitive decline.
    Riedel WJ; Jolles J
    Drugs Aging; 1996 Apr; 8(4):245-74. PubMed ID: 8920174
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Part III. Developmental disorders, alternative approaches, and emerging technologies.
    Handb Exp Pharmacol; 2015; 228():305-7. PubMed ID: 26317141
    [No Abstract]   [Full Text] [Related]  

  • 68. Assessing cognitive improvement in people with Down syndrome: important considerations for drug-efficacy trials.
    Fernandez F; Reeves RH
    Handb Exp Pharmacol; 2015; 228():335-80. PubMed ID: 25977089
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The use of EEG parameters as predictors of drug effects on cognition.
    Blokland A; Prickaerts J; van Duinen M; Sambeth A
    Eur J Pharmacol; 2015 Jul; 759():163-8. PubMed ID: 25823806
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans.
    Lupien SJ; Gillin CJ; Hauger RL
    Behav Neurosci; 1999 Jun; 113(3):420-30. PubMed ID: 10443770
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anosmia in COVID-19 could be associated with long-term deficits in the consolidation of procedural and verbal declarative memories.
    Llana T; Mendez M; Zorzo C; Fidalgo C; Juan MC; Mendez-Lopez M
    Front Neurosci; 2022; 16():1082811. PubMed ID: 36570827
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bridging neurocognitive aging and disease modification: targeting functional mechanisms of memory impairment.
    Gallagher M; Bakker A; Yassa MA; Stark CE
    Curr Alzheimer Res; 2010 May; 7(3):197-9. PubMed ID: 20088811
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The quest for a smart pill.
    Hall SS
    Sci Am; 2003 Sep; 289(3):54-7, 60-5. PubMed ID: 12951828
    [No Abstract]   [Full Text] [Related]  

  • 74. How should we measure nutrition-induced improvements in memory?
    Benton D; Kallus KW; Schmitt JA
    Eur J Nutr; 2005 Dec; 44(8):485-98. PubMed ID: 16331358
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treating chemobrain: rehabilitation therapies emerge.
    McNeil C
    J Natl Cancer Inst; 2012 Nov; 104(22):1691-2. PubMed ID: 23111189
    [No Abstract]   [Full Text] [Related]  

  • 76. Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.
    Stone WS; Seidman LJ
    Schizophr Bull; 2008 Jan; 34(1):93-108. PubMed ID: 17504777
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Facts, events, and inflection: when language and memory dissociate.
    Miozzo M; Gordon P
    J Cogn Neurosci; 2005 Jul; 17(7):1074-86. PubMed ID: 16138432
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Cognitive dysfunction in elderly patients: diagnosis and treatment].
    Preobrazhenskaia IS; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(11):33-8. PubMed ID: 17176600
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.
    Millan MJ; Agid Y; Brüne M; Bullmore ET; Carter CS; Clayton NS; Connor R; Davis S; Deakin B; DeRubeis RJ; Dubois B; Geyer MA; Goodwin GM; Gorwood P; Jay TM; Joëls M; Mansuy IM; Meyer-Lindenberg A; Murphy D; Rolls E; Saletu B; Spedding M; Sweeney J; Whittington M; Young LJ
    Nat Rev Drug Discov; 2012 Feb; 11(2):141-68. PubMed ID: 22293568
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pre-clinical evaluation of cognition enhancing drugs.
    Schindler U
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S99-115. PubMed ID: 2694232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.